Literature DB >> 28512665

Involvement of µ-opioid Receptors and κ-opioid Receptors in Itch-related Scratching Behaviour of Imiquimod-induced Psoriasis-like Dermatitis in Mice.

Nobuaki Takahashi1, Mitsutoshi Tominaga, Ryohei Kosaka, Yayoi Kamata, Yoshie Umehara, Hironori Matsuda, Azumi Sakaguchi, Hideoki Ogawa, Kenji Takamori.   

Abstract

The pathogenesis of psoriatic itch is poorly understood. The aim of this study was to investigate the involvement of opioid receptors in scratching behaviour of imiquimod-induced psoriasis-like dermatitis model mice. Topical application of 5% imiquimod cream to the rostral back skin of mice induced antihistamine-resistant scratching behaviour. The expression of µ-opioid receptor (MOR) protein increased in the epidermis, dorsal root ganglia (DRG) and spinal cord of imiquimod-treated mice. In contrast, the expression of κ-opioid receptor (KOR) protein decreased in the DRG and spinal cord of imiquimod-treated mice, and was undetectable in the epidermis of both groups. Topical or intraperitoneal administration of the MOR antagonist naloxone and oral administration of the centrally acting KOR agonist ICI-199,441 inhibited scratching behaviour, whereas oral administration of the peri-pherally-selective KOR agonist asimadoline did not. These results suggest that peripheral and central MOR and central KOR may be involved in the modulation of scratching behaviour in imiquimod-treated mice.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28512665     DOI: 10.2340/00015555-2704

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  8 in total

1.  Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis.

Authors:  Saadet Inan; Alvaro Torres-Huerta; Liselotte E Jensen; Nae J Dun; Alan Cowan
Journal:  Eur J Pharmacol       Date:  2019-09-27       Impact factor: 4.432

2.  Role of neurturin in spontaneous itch and increased nonpeptidergic intraepidermal fiber density in a mouse model of psoriasis.

Authors:  Kent Sakai; Kristen M Sanders; Marina R Youssef; Kevin M Yanushefski; Liselotte E Jensen; Gil Yosipovitch; Tasuku Akiyama
Journal:  Pain       Date:  2017-11       Impact factor: 6.961

3.  Cholestatic pruritus: Emerging mechanisms and therapeutics.

Authors:  Sagar P Patel; Chirag Vasavda; Byron Ho; James Meixiong; Xinzhong Dong; Shawn G Kwatra
Journal:  J Am Acad Dermatol       Date:  2019-04-19       Impact factor: 11.527

Review 4.  Opioidergic Signaling-A Neglected, Yet Potentially Important Player in Atopic Dermatitis.

Authors:  Dorottya Ádám; József Arany; Kinga Fanni Tóth; Balázs István Tóth; Attila Gábor Szöllősi; Attila Oláh
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

Review 5.  Molecular and Cellular Mechanisms of Itch in Psoriasis.

Authors:  Eriko Komiya; Mitsutoshi Tominaga; Yayoi Kamata; Yasushi Suga; Kenji Takamori
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

Review 6.  Molecular Aspects of Pruritus Pathogenesis in Psoriasis.

Authors:  Kamila Jaworecka; Joanna Muda-Urban; Marian Rzepko; Adam Reich
Journal:  Int J Mol Sci       Date:  2021-01-16       Impact factor: 5.923

7.  Pruritus is common in patients with chronic liver disease and is improved by nalfurafine hydrochloride.

Authors:  Shuhei Yoshikawa; Takeharu Asano; Mina Morino; Keita Matsumoto; Hitomi Kashima; Yudai Koito; Takaya Miura; Yuko Takahashi; Rumiko Tsuboi; Takehiro Ishii; Haruka Otake; Junichi Fujiwara; Masanari Sekine; Takeshi Uehara; Kazuhito Yuhashi; Satohiro Matsumoto; Shinichi Asabe; Hiroyuki Miyatani; Hirosato Mashima
Journal:  Sci Rep       Date:  2021-02-04       Impact factor: 4.379

8.  Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease.

Authors:  Tadamichi Kawano; Masanori Atsukawa; Akihito Tsubota; Noritomo Shimada; Hidenori Toyoda; Koichi Takaguchi; Joji Tani; Asahiro Morishita; Atsushi Hiraoka; Shigeru Mikami; Toru Ishikawa; Hironao Okubo; Tsunamasa Watanabe; Tomomi Okubo; Taeang Arai; Korenobu Hayama; Norio Itokawa; Chisa Kondo; Katsuhiko Iwakiri
Journal:  Sci Rep       Date:  2022-05-04       Impact factor: 4.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.